Lowering the risk of Parkinson's disease with GLP-1 agonists and DPP4 inhibitors in type 2 diabetes

Brain. 2020 Oct 1;143(10):2868-2871. doi: 10.1093/brain/awaa287.

Abstract

This scientific commentary refers to ‘Diabetes medications and risk of Parkinson’s disease: a cohort study of patients with diabetes’, by Brauer etal. (doi:10.1093/brain/awaa262).

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Cohort Studies
  • Diabetes Mellitus, Type 2* / drug therapy
  • Dipeptidyl Peptidase 4
  • Dipeptidyl-Peptidase IV Inhibitors* / therapeutic use
  • Glucagon-Like Peptide 1
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Parkinson Disease* / drug therapy

Substances

  • Dipeptidyl-Peptidase IV Inhibitors
  • Hypoglycemic Agents
  • Glucagon-Like Peptide 1
  • DPP4 protein, human
  • Dipeptidyl Peptidase 4